In the depths of winter, a warm front of hope swept through Delaware and Southern New Jersey, not with the changing climate but through the dedicated efforts of all who supported VA’s Veterans Experience Action Center, or VEAC. From Dec. 12-14, a virtual VEAC event became a nexus of support, serving 228 Veterans with dedication…
Embrace the new year with the Caregiver Support Program
The Caregiver Support Program (CSP) wishes all Veterans’ caregivers a happy new year and a warm welcome to 2024. CSP offers resources to support caregivers and their goals, no matter how big or small. “At the heart of our mission lies a steadfast commitment to the health and well-being of caregivers who selflessly support our…
Revolutionizing lung care: Robotic-assisted bronchoscopy
Lung cancer presents a critical health care concern for Veterans who have a 25% higher likelihood of diagnosis compared to non-Veterans. It ranks as the leading cause of cancer-related deaths, claiming the lives of approximately 15 Veterans each day. To address this alarming trend, South Texas VA has implemented cutting-edge technology for early detection and…
Knowledge Graphs Can Move Healthcare into the Future
The term knowledge graph may not be part of your everyday vocabulary, but if you are interested in digital health, it’s worth taking a closer look. By John Halamka, M.D., President, Mayo Clinic Platform and Paul Cerrato, MA, senior research analyst and communications specialist, Mayo Clinic Platform. IBM defines a knowledge graph (KG) as “a…
Prompt Engineering Can Improve the Performance of Generative AI
No sensible clinician would ever allow a large language model to replace them at the bedside, but those who want to use these digital tools to supplement their decision making might benefit from prompt engineering. By John Halamka, M.D., President, Mayo Clinic Platform, and Paul Cerrato, senior research analyst and communications specialist, Mayo Clinic Platform.…
Can Large Language Models Offer Intelligent Clinical Reasoning?
At face value, LLMs seem to exhibit the logical, analytical skills of experienced clinicians. But trying to comprehend what’s “under the hood” remains a challenge. By Paul Cerrato, senior research analyst and communications specialist, Mayo Clinic Platform, and John Halamka, M.D., President, Mayo Clinic Platform. Shakespeare once said “All that glitters is not gold.” Many…
AI Regulations Require a Nuanced Approach
The U.S. government and the European Union both realize the need for measured control over the latest technology. Implement too many regulations too quickly and you stifle innovation. Move too slowly and you risk harm from irresponsible players in the field. By John Halamka, M.D., President, Mayo Clinic Platform, and Paul Cerrato, senior research analyst…
Understanding Retrieval-Augmented Generation
This digital tool may help healthcare professionals obtain safer, more reliable replies to their large language model prompts. By John Halamka, M.D., President, Mayo Clinic Platform, and Paul Cerrato, senior research analyst and communications specialist, Mayo Clinic Platform. With so many thought leaders raising concerns about the possibility of large language models (LLMs) fabricating data…
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Conditions: Influenza; COVID-19 Interventions: Biological: Influenza and COVID-19 Combination A; Biological: Licensed influenza vaccine; Biological: COVID-19 Vaccine; Biological: Influenza and COVID-19 Combination B; Biological: Placebo Sponsors: BioNTech SE; Pfizer Not yet recruiting Author:
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
Conditions: Respiratory Syncytial Virus Interventions: Biological: mRNA-1345; Biological: Placebo Sponsors: ModernaTX, Inc. Recruiting Author:
INcreased Sun Exposure Without Pain In Research Subjects With EPP
Conditions: Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) Interventions: Drug: Dersimelagon; Drug: Placebo Sponsors: Mitsubishi Tanabe Pharma America Inc. Recruiting Author:
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Conditions: NonSegmental Vitiligo Interventions: Drug: Povorcitinib; Drug: Placebo Sponsors: Incyte Corporation Recruiting Author: